| 1. |
Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res, 2013, 19(8): 2240-2247.
|
| 2. |
Marcoux N, Gettinger SN, O'Kane G, et al. EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes. J Clin Oncol, 2019, 37(4): 278-285.
|
| 3. |
Wang WX, Xu CW, Chen HF, et al. Genomic alterations and clinical outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after treatment with EGFR tyrosine kinase inhibitors: A multicenter retrospective study. Lung Cancer, 2021, 155: 20-27.
|
| 4. |
Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med, 2005, 352(8): 786-792.
|
| 5. |
Wu SG, Liu YN, Tsai MF, et al. The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients. Oncotarget, 2016, 7(11): 12404-12413.
|
| 6. |
Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science, 2007, 316(5827): 1039-1043.
|
| 7. |
Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med, 2011, 3(75): 75ra26.
|
| 8. |
Levacq D, D'Haene N, de Wind R, et al. Histological transformation of ALK rearranged adenocarcinoma into small cell lung cancer: a new mechanism of resistance to ALK inhibitors. Lung Cancer, 2016, 102: 38-41.
|
| 9. |
Shiao TH, Chang YL, Yu CJ, et al. Epidermal growth factor receptor mutations in small cell lung cancer: a brief report. J Thorac Oncol, 2011, 6(1): 195-198.
|
| 10. |
Tatematsu A, Shimizu J, Murakami Y, et al. Epidermal growth factor receptor mutations in small cell lung cancer. Clin Cancer Res, 2008, 14(19): 6092-6096.
|
| 11. |
Niederst MJ, Sequist LV, Poirier JT, et al. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nat Commun, 2015, 6: 6377.
|
| 12. |
Ferrer L, Giaj Levra M, Brevet M, et al. A brief report of transformation from NSCLC to SCLC: molecular and therapeutic characteristics. J Thorac Oncol, 2019, 14(1): 130-134.
|
| 13. |
Takuma S, Inoue Y, Karayama M, et al. EGFR-mutated lung adenocarcinoma successfully treated with osimertinib after spontaneous transformation to SCLC and adenocarcinoma with neuroendocrine differentiation: case report. JTO Clin Res Rep, 2022, 3(1): 100264.
|
| 14. |
Lee JK, Lee J, Kim S, et al. Clonal history and genetic predictors of transformation into small-cell carcinomas from lung adenocarcinomas. J Clin Oncol, 2017, 35(26): 3065-3074.
|
| 15. |
Offin M, Chan JM, Tenet M, et al. Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes. J Thorac Oncol, 2019, 14(10): 1784-1793.
|
| 16. |
Pignataro D, Bertaglia V, Bironzo P, et al. Oligoprogressive disease with SCLC transformation in EGFR-mutated NSCLC: how biology knowledge can change the game rules. J Thorac Oncol, 2020, 15(10): e170-e172.
|
| 17. |
Le XN, Negrao MV, Reuben A, et al. Characterization of the immune landscape of EGFR-mutant NSCLC identifies CD73/adenosine pathway as a potential therapeutic target. J Thorac Oncol, 2021, 16(4): 583-600.
|
| 18. |
Zhou J, Yu X, Hou LK, et al. Epidermal growth factor receptor tyrosine kinase inhibitor remodels tumor microenvironment by upregulating LAG-3 in advanced non-small-cell lung cancer. Lung Cancer, 2021, 153: 143-149.
|
| 19. |
Mahadevan NR, Knelson EH, Wolff JO, et al. Intrinsic immunogenicity of small cell lung carcinoma revealed by its cellular plasticity. Cancer Discov, 2021, 11(8): 1952-1969.
|
1/5
WeChat